Curiously, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), seemingly disparate neurodegenerative disorders, can be inherited together. Two groups (DeJesus-Hernandez et al. and Renton et al.) show that the long sought after ALS/FTD mutation on chromosomal region 9p is a hexanucleotide expansion in C90RF72. These studies, plus a study on X-linked ALS/FTD, provide molecular starting points for identifying pathways that link ALS and FTD pathogenesis.
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At first glance, one might think that a paralytic disease caused by degeneration of upper and lower motor neurons, amyotrophic lateral sclerosis (ALS), is unlikely to be linked mechanistically to a disease that presents with progressive changes in personality and language, frontotemporal dementia (FTD). Mutations in superoxide dismutase 1 (SOD1), TAR DNAbinding protein , fused in sarcoma (FUS), optineurin (OPTN), and valosin-containing protein (VCP) cause about 25%-30% of typical familial ALS, and loss-of-function mutations in the secreted growth factor progranulin cause a fraction of familial FTD. Yet clinically, ALS and FTD frequently occur in the same family. Moreover, abnormal subcellular localization and aggregation of TDP-43 are found in most patients with ALS and FTD. Perhaps not surprisingly, this is a landscape that would attract teams of gene hunters. In this issue of Neuron, two groups (DeJesus- Hernandez et al., 2011; Renton et al., 2011) show that the illusive chromosomal region 9p21 form of ALS/FTD is due to an expansion of a hexanucleotide repeat in the intron of C90RF72. Combined with the report last month in Nature by Deng et al. (2011) that an X-linked form of ALS and ALS/ FTD is caused by mutations in UBQLN2, there is now strong evidence that these two disorders are indeed linked by common pathogenic pathways.
Genetic studies dating back to 2006 indicated that a major locus for ALS/FTD is located on chromosomal region 9p21 (Vance et al., 2006) . Using two distinctive next-generation DNA sequencing strategies, groups headed by Rosa Rademakers and Bryan Traynor identified a GGGGCC hexanucleotide repeat in the intron between noncoding exons 1a and 1 b of the long transcript C90RF72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . Wild-type alleles contain no more than 23 repeats, whereas affected alleles have greater than 30 repeats. Identification of the 9p21 disease-causing mutation allowed these groups to determine the frequency of this mutation in patient populations. The two studies each clearly show that the repeat expansion in C90RF72 is a major cause of FTD and ALS. Using material collected at the Mayo Clinic, the University of British Columbia, and the University of California-San Francisco DeJesus-Hernandez et al. (2011) found that this expansion was in almost 12% of familial FTD and 22.5% of familial ALS. Likewise, Renton et al. (2011) found that C90RF72 repeat expansion is associated with 46% of familial ALS, 21.1% of sporadic ALS, and 29.3% of FTD in the Finnish population. In an outbred European population they found that one third of ALS patients have an expanded GGGGCC repeat.
As of now, little is known about C90RF72. It is highly conserved across species yet the C90RF72 protein remains uncharacterized. This likely will change very quickly. In any case, location of the GGGGCC repeat within an intron along with some evidence for alternative splicing of C90RF72 transcripts brings into to play a prominent aspect of noncoding repeat expansion disorders-the role of RNA metabolism in pathogenesis. Specifically, the pathogenic role of the mutant RNA itself becomes a strong candidate for having a role in the development of ALS/FTD.
The myotonic dystrophies DM1 and DM2 are model RNA-mediated disorders (Todd and Paulson, 2010 These features of DM1 will likely form the foundation for the next experimental steps to be pursued with C90RF72 and its role in ALS/FTD. In fact, the observation by DeJesus-Hernandez et al. (2011) that C90RF72 nuclear RNA foci can be detected in ALS/FTD patient tissue is an important first step and starts this ball rolling. Among the more crucial next points will be to determine whether the C90RF72 RNA is pathogenic and, if so, identify proteins to which it binds.
Given that TDP-43 pathology is a feature of ALS/FTD and TDP-43 is a RNAbinding protein, it would be very parsimonious if TDP-43 were to bind the C90RF72 transcript. However, based on what is known about the binding of TDP-43 to target RNAs, i.e., TDP-43 prefers long clusters of uridine, guanine dinucleotiderich regions (Tollervey et al., 2011; Polymenidou et al., 2011) , it seems unlikely that it binds directly to the C90RF72 GGGGCC repeat. Alternatively, TDP-43 might bind to other regions of the C90RF72 transcript or be in a complex with another RNA-binding protein that does bind to the C90RF72 transcript.
What about UBQLN2 and the X-linked form of ALS and ALS/FTD reported by Deng et al. (2011) ? Clearly, the presence of an additional genetic locus where mutations lead to patients with ALS and FTD together strengthens the concept that these apparently divergent disorders are related mechanistically. However, a pivotal question is whether it provides any further insight into mechanism(s) that might link up with C90RF72 and perhaps a mutant RNA. UBQLN2 encodes ubiquilin 2, which is a member of a family of proteins that have both a ubiquitin-like domain and a ubiquitin-associated domain. As such, these proteins are thought to deliver ubiquitinated proteins to the proteasome for degradation. Two additional findings by Deng et al. (2011) are worth noting. First, the ALS/FTDassociated mutations in UBQLN2, at least as assessed with transiently transfected neuro-2a cells, resulted in a decreased ability to degrade an ubiquitin-proteasome reporter substrate. In addition, they also found evidence in transfected neuro-2A cells that either wild-type or mutant ubiquilin 2 formed aggregates with TDP-43. This latter observation suggests that ubiquilin 2 might in some way be involved in a TDP-43 pathway. In this regard, it is worth noting that ubiquitination of TDP-43 is a feature found in the brains of patients with TDP-43 pathology, e.g., ALS and FTD (Neumann et al., 2006) . Whether ubiquilin 2 functions in regulating the degradation of TDP-43 would seem to merit exploration.
It is abundantly clear that on many levels TDP-43 is an important protein that links ALS with FTD. Thus, understanding the function of TDP-43 and how it is altered in ALS and FTD will be critical for understanding the pathogenesis of these two disorders as well understanding why ALS and FTD can present simultaneously in a patient. The bet is that elucidation of the pathogenic mechanism stemming from expansion of the hexanucleotide repeat in C90RF72 will have a pivotal role in putting this puzzle together. This effort will further underscore the seminal role RNA processing plays in neurodegeneration.
